. Invasion of differentiated thyroid cancer (DTC) into surrounding structures can lead to morbid procedures such as laryngectomy and tracheal resection. In these patients, there is a potential role for neoadjuvant therapy. . We identified three studies involving the treatment of DTC with neoadjuvant chemotherapy: two from Slovenia and one from Japan. . These studies demonstrate that in selected situations, neoadjuvant chemotherapy can have a good response and allow for a more complete surgical resection, the treatment of DTC. Additionally, the SELECT trial shows that the targeted therapy lenvatinib is effective in the treatment of DTC and could be useful as neoadjuvant therapy for this disease due to its short time to response. Pazopanib has also demonstrated promise in phase II data. . Thus, chemotherapy in the neoadjuvant setting could possibly be useful for managing advanced DTC. Additionally, some of the new tyrosine kinase inhibitors (TKIs) hold promise for use in the neoadjuvant setting in DTC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055971 | PMC |
| http://dx.doi.org/10.1155/2016/3743420 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?
J Clin Oncol
January 2025
Aaron J. Scott, MD, University of Arizona Cancer Center, Tucson, AZ; Erin B. Kennedy, MHSc, American Society of Clinical Oncology, Alexandria, VA; and Sepideh Gholami, MD, MAS, Northwell Health, New Hyde Park, NY.
Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?
J Clin Oncol
January 2025
Mahsoem Ali, BSc; and Lenka N.C. Boyd, MD, Amsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands, Amsterdam UMC, Location Vrije Universiteit, Department of Medical Oncology, Lab of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Elisa Giovannetti, MD PhD, Amsterdam UMC, Location Vrije Universiteit, Department of Medical Oncology, Lab of Medical Oncology, Amsterdam, the Netherlands, Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands, Cancer Pharmacology Lab, AIRC Start-Up Unit, Fondazione Pisa per la Scienza, Pisa, Italy; and Geert Kazemier, MD, PhD, Amsterdam UMC, Location Vrije Universiteit, Department of Surgery, Amsterdam, the Netherlands, Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.
Background: Identifying risk factors for local recurrence (LR) is pivotal in optimizing rectal cancer treatment. Total mesorectal excision (TME) and lateral lymph node dissection (LLND) are the standard treatment for advanced low rectal cancer in Japan. However, large-scale studies to evaluate risk factors for LR are limited.
View Article and Find Full Text PDFIndole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer.
Front Oncol
December 2024
Research Institute of Internal Medicine and Norwegian PSC Research Center, Division of Surgery and Specialized Medicine, Oslo University Hospital, Oslo, Norway.
Background/aims: It was recently reported that a higher concentration of the bacterially produced metabolite indole 3-acetate (3-IAA) in blood was linked to a better response to chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Here, we aimed to extend these observations to patients diagnosed with non-metastatic PDAC.
Method: We measured circulating 3-IAA in samples from a prospective population-based cohort of 124 patients with borderline resectable or locally advanced PDAC, collected before initiating neoadjuvant chemotherapy.
Enhancing clinical complete response assessment in rectal cancer: integrating transanal multipoint full-layer puncture biopsy criteria: a systematic review.
Front Oncol
December 2024
Department of Generall Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
There is currently a lack of standardized criteria for evaluating clinical complete response (cCR) in rectal cancer post-neoadjuvant chemoradiotherapy (nCRT), often resulting in discrepancies with true pathological complete response (pCR). Staging local lesions via MRI is challenged by tissue edema and fibrosis post-nCRT, while endoscopic biopsy accuracy is compromised by residual cancer foci in the muscular layer. Transanal local excision offers a relatively accurate assessment of lesion regression but poses challenges including impaired anal function and elevated complication rates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!